RaySearch Laboratories (RAY-B.ST) Stock Analysis & AI Equity Report
RaySearch Laboratories (RAY-B.ST) overview
RaySearch Laboratories (RAY-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, RaySearch Laboratories reported revenue of SEK 1,344m and operating profit of SEK 322m; the year-end share price was 228.00 SEK and market capitalisation was SEK 7,810m. RaySearch Laboratories is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get RaySearch Laboratories's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About RaySearch Laboratories
RaySearch Laboratories is a medical technology company that develops software for improved cancer treatment. Its main products include the RayStation treatment planning system, the RayCare oncology information system, RayIntelligence analytics software, and RayCommand treatment control software. The company sells these solutions to cancer clinics worldwide and also works with partners in radiotherapy and oncology workflows.
Generate the RaySearch Laboratories report
RaySearch Laboratories is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for RaySearch Laboratories and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.